Related Experiment Videos
[Long-term treatment of hypertension with a selective beta-1-blockader without sympathomimetic activity. II. Changes
Insights
Six months of Betaloc (Metoprolol) treatment effectively reduced left ventricular hypertrophy in hypertensive patients. This beta-blocker therapy improved cardiac function by decreasing ventricular mass and enhancing ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Context:
- Hypertension is a significant risk factor for cardiovascular disease, often leading to left ventricular hypertrophy (LVH).
- LVH is associated with impaired diastolic and systolic function, increasing the risk of heart failure.
- Selective beta-1 blockers are commonly used to manage hypertension and its cardiac consequences.
Purpose:
- To investigate the long-term effects of Betaloc (Metoprolol), a selective beta-1 blocker, on left ventricular structure and function.
- To assess the impact of 6 months of treatment on echocardiographic parameters in hypertensive patients with LVH.
- To evaluate the potential of Betaloc in reversing cardiac remodeling and improving ventricular performance.
Summary:
- Thirty patients with stage II hypertension and echocardiographically confirmed LVH received 6 months of Betaloc treatment.
- Significant reductions were observed in septal and posterior wall thickness, left ventricular mass, and end-systolic dimensions and volume.
- Ejection fraction and shortening fraction increased significantly, indicating improved systolic function, while isovolumetric relaxation time shortened, suggesting enhanced diastolic function.
Impact:
- Prolonged Betaloc treatment effectively reverses left ventricular hypertrophy in hypertensive patients.
- The study demonstrates significant improvements in both systolic and diastolic left ventricular function.
- Betaloc's mechanism involves controlling arterial pressure and reducing cardiac sympathetic stimulation, leading to favorable cardiac remodeling.
Abstract:
The effect of the 6 months long treatment with the Hungarian selective beta-1-blocker Betaloc (Metoprolol) on the structure and function of the left ventricle was studied in 30 hypertensive patients--II stage (with echocardiographically proved left ventricular hypertrophy) by means of simultaneous recording of M-type echocardiogram, ACG, PCG and ECG. The telediastolic thickness of the septum and the posterior wall and the left ventricular muscular mass decrease at the end of the 6-th month (p less than 0.0001). The telesystolic dimension and volume decrease (p less than 0.0001) in the 6-th month without changes in the telediastolic dimension and volume (p greater than 0.32). The shortening fraction and the ejection fraction increase (p less than 0.0001), Vcf increases insignificantly (p greater than 0.05). The isovolumetric relaxation shortens (p less than 0.0001), the active suction period lengthens (p less than 0.0001) as well as the fast filling period (p less than 0.0027). By controlling the arterial pressure and suppressing the sympathetic stimulation of the heart the prolonged Betaloc treatment leads to reversion of the hypertrophy and improves the left ventricular function.